The Biology of Autism — a Series
Autism is not one thing.
A common assumption is that the condition has a single cause and a single story. Our research points to something more granular: four distinct biological strands can underlie autism-related symptoms — a brain-energy deficit, an immune-mediated subset, a wiring difference, and acquired features that are not developmental. Different patients likely carry different combinations of these, and each contributes a different slice of the daily symptom burden.
This series examines each strand in plain language, then asks the question they all converge on: can several pathways be treated at once to remove or dampen symptoms and give the patient a more normal life?
1 What we know, what our research adds
Every article in this series distinguishes two things clearly:
- What we know — established scientific findings, cited to the peer-reviewed literature (the mitochondrial evidence in autism (Frye et al. 2024), the BH4 finding (Colpani Filho et al. 2025), the maternal-antibody evidence (Braunschweig et al. 2013), and the cerebellar glutamatergic genetic signal (Maccallini 2026)).
- What our research adds — the hypotheses our documentation project developed by reading across disease boundaries, and which are not yet established: the brain-energy convergence model, the multi-pathway treatment hypothesis, the neuroimmune-encephalopathy-spectrum framework, and the acquired-vs-developmental distinction.
The distinction matters because the two are not the same confidence. “What we know” is evidence; “what our research adds” is testable hypothesis. The series keeps them separate so you are never misled into treating a hypothesis as a finding.
Each article follows the same shape:
- What it is — the mechanism, in ordinary words.
- The evidence — what supports it, and how strong that evidence is.
- The honest limits — what it does not claim.
- The decisive experiment — how the idea could be confirmed or refuted.
2 Part 1: Autism as a Brain Energy Disorder — and the Multi-Pathway Treatment Hypothesis
The series opens with the most developed strand: a brain running on a thin fuel supply. When the brain cannot afford its most energy-expensive operations — filtering noise, switching tasks, reading faces — it economizes, and those economized functions are exactly the ones we recognize as core to autism. Part 1 also carries the series’ synthesis: the multi-pathway treatment hypothesis, and what treating several mechanisms at once could mean.
Read the article:
- Autism as a Brain Energy Disorder: What the Science Says — the astrocyte/GLUT1 model, the mitochondrial and BH4 evidence, the modifiable targets, the honest limits, the CSF:glucose decisive experiment, and the multi-pathway treatment hypothesis.
3 Part 2: The Immune-Mediated Subset of Autism
Not all autism may have the same cause. A subset may be driven by the immune system — maternal antibodies targeting fetal brain proteins during development, or infection-triggered anti-neuronal responses after birth. The key finding: immunotherapy works in antibody-stratified patients but not in unselected ones. The subset matters because it is potentially identifiable and treatable.
Read the article:
- The Immune-Mediated Subset of Autism: When the Immune System Shapes the Brain — the maternal-antibody route, the postnatal route, the IVIG stratification evidence, the neuroimmune-encephalopathy-spectrum framework, and the decisive multi-disease antibody study.
4 Part 3: The Cerebellar-Glutamate Connection
A third strand is neither a fuel problem nor an immune problem: a wiring-level difference in the cerebellum and in glutamatergic circuits — the brain’s excitatory pathways. Cerebellar Purkinje cell loss is among the most replicated findings in autism, and a genetic signal links it to sensory sensitivity. This strand is explanatory and diagnostic, not yet a treatment target.
Read the article:
- The Cerebellar-Glutamate Connection in Autism: A Wiring-Level Hypothesis — the Purkinje-cell evidence, the glutamatergic genetic signal, the shared features, the testable sensory-sensitivity prediction, and the honest limits.
5 Part 4: Acquired vs. Developmental — When Autism-Like Features Might Be Reversible
The clinically consequential question: are autism-like features necessarily present from development, or can some be acquired — and therefore reversible? Sensory rigidity, withdrawal, and apparent alexithymia can arise after development rather than from it. Telling the two apart determines whether a symptom might respond to treating its cause or is stable wiring.
Read the article:
- Acquired vs. Developmental: When Autism-Like Features Might Be Reversible — the interoceptive mechanism, the neuroinflammation route, the context-dependence test, and the clinical consequences of getting the distinction wrong.
6 A note on honesty
Every article in this series distinguishes carefully what is confirmed by evidence, what is a promising hypothesis, and what is an individual patient’s experience. Most of the content here is at the hypothesis end — the certainties are explicit, often low, and nothing is presented as established clinical fact or a treatment recommendation.
The underlying science is drawn from our documentation project, which develops these cross-disease energy and immune models in detail. The autism-specific framing is our reading of the literature, written to stand alone for anyone curious about the biology.
Discuss any medical decision with a qualified clinician.